Nazaret Cobos-Trigueros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Nazaret Cobos-Trigueros has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alex Soriano
Hospital Clínic of Barcelona, Barcelona, Spain
1 shared publication - Andrea Vergara
Microbiology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain; Institute of Global Health (ISGlobal), Barcelona, Spain; CIBERINFEC, CIBER in Infectious Diseases, ISCIII, Madrid, Spain; University of Barcelona, Faculty of Medicine, Barcelona, Spain
1 shared publication - Caterina Mata
Izasa
1 shared publication - Catia Cilloniz
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
1 shared publication - Francesc Marco
Department of Clinical Microbiology, Hospital Clinic‐CDB Universitat de Barcelona Barcelona Spain
1 shared publication - Jordi Vila
Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain; CIBERINFEC, Instituto Salud Carlos III, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Magicplex TM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
Sepsis is a serious health condition worldwide, affecting more than 30 million people globally each year. In 2017, the World Health Organization (WHO) adopted a resolution on sepsis: “improving the prevention, diagnosis and clinical management of sepsis”, with the aim of improving early diagnosis, management and prevention to save lives. Blood culture (BC) is generally used to diagnose sepsis because of the low quantity of microbes occurring in the blood during such infections. However, approximately 50% of bloodstream infections (BSI) give negative BC, this figure being higher for sepsis, which delays the start of appropriate antimicrobial therapy. This prospective study evaluated a multiplex real-time polymerase chain reaction, the Magicplex TM Sepsis test (MP), for the detection of pathogens from whole blood, comparing it to routine BC. We analysed 809 blood samples from 636 adult patients, with 132/809 (16.3%) of the samples positive for one or more relevant microorganism according to BC and/or MP. The sensitivity and specificity of MP were 29% and 95%, respectively, while the level of agreement between BC and MP was 87%. The rate of contaminated samples was higher for BC (10%) than MP (4.8%) ( P < 0.001). Patients with only MP-positive samples were more likely to be on antimicrobial treatment (47%) than those with only BC-positive samples (18%) ( P = 0.002). In summary, the MP test reduces the time taken to identify the microbial pathogen, improving the diagnosis of BSI in patients on antibiotic treatment.
Open AccessMagicplex TM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
Sepsis is a serious health condition worldwide, affecting more than 30 million people globally each year. In 2017, the World Health Organization (WHO) adopted a resolution on sepsis: “improving the prevention, diagnosis and clinical management of sepsis”, with the aim of improving early diagnosis, management and prevention to save lives. Blood culture (BC) is generally used to diagnose sepsis because of the low quantity of microbes occurring in the blood during such infections. However, approximately 50% of bloodstream infections (BSI) give negative BC, this figure being higher for sepsis, which delays the start of appropriate antimicrobial therapy. This prospective study evaluated a multiplex real-time polymerase chain reaction, the Magicplex TM Sepsis test (MP), for the detection of pathogens from whole blood, comparing it to routine BC. We analysed 809 blood samples from 636 adult patients, with 132/809 (16.3%) of the samples positive for one or more relevant microorganism according to BC and/or MP. The sensitivity and specificity of MP were 29% and 95%, respectively, while the level of agreement between BC and MP was 87%. The rate of contaminated samples was higher for BC (10%) than MP (4.8%) ( P < 0.001). Patients with only MP-positive samples were more likely to be on antimicrobial treatment (47%) than those with only BC-positive samples (18%) ( P = 0.002). In summary, the MP test reduces the time taken to identify the microbial pathogen, improving the diagnosis of BSI in patients on antibiotic treatment.